Neuphoria Therapeutics Inc. (ticker: NEUP) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of NEUP's SEC filings surfaces 3 active risk signals, including 1 auditor-change signal, 1 delisting/deregistration signal, and 1 late-filing signal. NEUP reported $15.65M in revenue and -$8.04M for the period ending 2025-06-30, with operating cash flow of -$10.23M. Cash and equivalents stood at $22.17M (up 410.3% year-over-year). Total assets of $36.60M exceed total liabilities of $6.90M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
NEUP SEC Filings
Full cached SEC EDGAR filing history for NEUP, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.